Actuate Therapeutics, Inc. (ACTU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.48+8.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ACTU
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Operating Expenses & Income | |||||
| R&D Expenses | 8.9 | 10.3 | 18.7 | 21.7 | — |
| Operating Income | (20.8) | (22.5) | (25.2) | (25.0) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | 0.0 | 0.0 | — | — |
| Interest & Investment Income | 0.3 | 0.3 | 0.2 | 0.4 | — |
| Other Non-Operating Income / Expenses | 0.3 | 0.3 | (2.1) | 0.2 | — |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||
| Net Income | (20.5) | (22.2) | (27.3) | (24.7) | — |
| Per Share | |||||
| Basic EPS | (0.86) | (1.06) | (3.26) | (17.24) | — |
| Diluted EPS | (0.86) | (1.06) | (3.26) | (17.24) | — |
| Basic Weighted Avg Shares | 23.9 | 21.0 | 8.4 | 1.4 | — |
| Diluted Weighted Avg Shares | 23.9 | 21.0 | 8.4 | 1.4 | — |
| Supplemental | |||||
| EBIT | (20.8) | (22.5) | (25.2) | (25.0) | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.